Literature DB >> 22854671

Hepatitis A vaccine should receive priority in National Immunization Schedule in India.

Ramesh Verma1, Pardeep Khanna.   

Abstract

Hepatitis A is an acute, usually self-limiting infection of the liver caused by a virus known as hepatitis A virus (HAV). Humans are the only reservoir of the virus; transmission occurs primarily through the fecal-oral route and is closely associated with poor sanitary conditions. The virus has a worldwide distribution and causes about 1.5 million cases of clinical hepatitis each year. The risk of developing symptomatic illness following HAV infection is directly correlated with age. As many 85% of children below 2 y and 50% of those between 2-5 y infected with HAV are anicteric, and among older children and adults, infection usually causes clinical disease, with jaundice occurring in more than 70% of cases. The infection is usually self-limiting with occasional fulminant hepatic failure and mortality. In most developing countries in Asia and Africa, hepatitis A is highly endemic such that a large proportion of the population acquires immunity through asymptomatic infection early in life. HAV is endemic in India; most of the population is infected asymptomatically in early childhood with life-long immunity. Several outbreaks of hepatitis A in various parts of India have been recorded in the past decade such that anti-HAV positivity varied from 26 to 85%. Almost 50% of children of ages 1-5 y were found to be susceptible to HAV. Any one of the licensed vaccines may be used since all have nearly similar efficacy and safety profiles (except for post-exposure prophylaxis / immunocompromised patients, where only inactivated vaccines may be used). Two doses 6 mo apart are recommended for all vaccines. All Hepatitis A vaccines are licensed for use in children aged 1 y or older. However in the Indian scenario, it is preferable to administer the vaccines at age 18 mo or more when maternal antibodies have completely declined. Vaccination at this age is preferable to later since it is easier to integrate with the existing schedule, protects those who have no antibodies, and protects children by the time they attend day care. In India the vaccine against hepatitis A is available for the people who can afford it, but the government of India should give this vaccine as a priority in the national immunization schedule.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22854671      PMCID: PMC3551887          DOI: 10.4161/hv.20475

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  14 in total

1.  Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence.

Authors:  K Van Herck; P Van Damme
Journal:  J Med Virol       Date:  2001-01       Impact factor: 2.327

2.  Seroprevalence of antibodies to hepatitis A virus among children in Northern India.

Authors:  R Aggarwal; S Naik; S K Yachha; S R Naik
Journal:  Indian Pediatr       Date:  1999-12       Impact factor: 1.411

3.  Changing epidemiology of hepatitis A and hepatitis E in urban and rural India (1982-98).

Authors:  V A Arankalle; M S Chadha; S D Chitambar; A M Walimbe; L P Chobe; S S Gandhe
Journal:  J Viral Hepat       Date:  2001-07       Impact factor: 3.728

4.  Seroepidemiology of hepatitis A infection in India: changing pattern.

Authors:  M L Mall; R R Rai; M Philip; G Naik; P Parekh; S C Bhawnani; B Olowokure; M Shamanna; J Weil
Journal:  Indian J Gastroenterol       Date:  2001 Jul-Aug

5.  Prevalence of hepatitis a antibodies in western Indian population: changing pattern.

Authors:  S D Chitambar; M S Chadha; M S Joshi; V A Arankalle
Journal:  Southeast Asian J Trop Med Public Health       Date:  1999-06       Impact factor: 0.267

Review 6.  What did we learn from the Shanghai hepatitis A epidemic?

Authors:  W G Cooksley
Journal:  J Viral Hepat       Date:  2000-05       Impact factor: 3.728

7.  Molecular characterization of hepatitis A virus from a large outbreak from Kerala, India.

Authors:  V A Arankalle; K L Sarada Devi; K S Lole; K T Shenoy; V Verma; M Haneephabi
Journal:  Indian J Med Res       Date:  2006-06       Impact factor: 2.375

8.  Changing seroepidemiology of hepatitis A virus infection in Taiwan.

Authors:  H Y Hsu; M H Chang; D S Chen; C Y Lee; J L Sung
Journal:  J Med Virol       Date:  1985-12       Impact factor: 2.327

Review 9.  Epidemiological patterns of hepatitis A in different parts of the world.

Authors:  I D Gust
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

10.  The declining transmission of hepatitis A in Thailand.

Authors:  B L Innis; R Snitbhan; C H Hoke; W Munindhorn; T Laorakpongse
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

View more
  12 in total

1.  Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose.

Authors:  Xiaoshu Zhang; Jing An; Aixia Tu; Xuefeng Liang; Fuqiang Cui; Hui Zheng; Yu Tang; Jianfeng Liu; Xuxia Wang; Ningjing Zhang; Hui Li
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

2.  Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.

Authors:  Hemat Jain; Vandana Kumavat; Tejinder Singh; Amanda Versteilen; Michal Sarnecki
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Vaccination during pregnancy: Today's need in India.

Authors:  Ramesh Verma; Pardeep Khanna; Mukesh Dhankar
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

4.  Viral hepatitis: Indian scenario.

Authors:  Sandeep Satsangi; Yogesh K Chawla
Journal:  Med J Armed Forces India       Date:  2016-08-09

5.  Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.

Authors:  Philip R Spradling; Lisa R Bulkow; Susan E Negus; Chriss Homan; Michael G Bruce; Brian J McMahon
Journal:  Hepatology       Date:  2016-02-01       Impact factor: 17.425

Review 6.  Prevention of influenza in healthy children.

Authors:  Bruce Y Lee; Mirat Shah
Journal:  Expert Rev Anti Infect Ther       Date:  2012-10       Impact factor: 5.091

7.  Combating the wrath of viral hepatitis in India.

Authors:  Sandeep Satsangi; Radha K Dhiman
Journal:  Indian J Med Res       Date:  2016-07       Impact factor: 2.375

8.  Need for hepatitis A prevention in patients with chronic liver disease in the changing epidemiological setting of India.

Authors:  Bhaskar Raju; Anar Andani; Shafi Kolhapure; Ashish Agrawal
Journal:  Hum Vaccin Immunother       Date:  2020-11-25       Impact factor: 3.452

9.  A study of hepatitis A virus seropositivity among children aged between 1 and 5 years of age: Implications for universal immunization.

Authors:  Rakesh Gupta; R K Sanjeev; A Agarwal; R P S Tomar; N Kumar; Vipul Dutt; Shishir Gupta
Journal:  Med J Armed Forces India       Date:  2019-03-28

Review 10.  Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent.

Authors:  Ashish Agrawal; Sanjeev Singh; Shafi Kolhapure; Bernard Hoet; Vidya Arankalle; Monjori Mitra
Journal:  Infect Dis Ther       Date:  2019-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.